Opinion

The profitability of biopharma drug launches in the US will remain in decline until manufacturers reimagine their approach with payers

AI is a tool to make drug discovery cheaper, faster, and better — not a replacement for human ingenuity.

Due to increasing complexity of modern technology, FDA should consider updating its 510(k) process.

Key industry trends and how the relationships between companies and CDMOs are evolving to better meet the challenges of a BANI world.

By integrating support directly into existing workflows and focusing on solutions that eliminate "shoulder time," manufacturers can significantly reduce delays and improve patient outcomes.

Collaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.

Strategic imperatives for biotech firms in light of the latest market dynamics and investor behaviors.

Congress and our nation’s public health officials should take the current moment to self-reflect and resolve challenges with public confidence in our public and scientific institutions.

If you wish for your team to be diligent, innovative, and collaborative, you must first exhibit these traits yourself

Findings from hundreds of interviews of exceptional pharma leaders around the world.

The industry has struggled to recruit talent for years, and the challenge is only getting more difficult. Pharma companies need to recruit differently.

Delivering better patient outcomes hinges on innovation and adaptability.

Looking to hold an advisory board? Here are a few suggestions.

The era of big pharma as product-first companies must end, as services become the larger priority.

Tina Fresta, BA, MPH is the Strategic Solutions Senior Manager at epocrates, keeps a close eye on the pharmaceutical and bio science industry shifts, leveraging those insights to inform both our partners and our company of the most strategic approach to reach business goals.

With treatments becoming more complex, the life sciences industry needs more professionals with specialized knowledge.

Embrace the tools that solve real problems and make life easier.

One of the most special things about Pharmaceutical Executive®, in my opinion, is when people share their stories—where they came from; how their upbringing or education or background impacted their desire to work in pharma; any personal ties to their work, such as finding new treatments in a specific disease state due to a loved one having been impacted by that same disease; and just generally sharing their passion for their work. As someone who’s worked in pharma journalism for many years, there’s something extraordinary to hear about the why for individuals.

In this Q&A, Matt Smith, vice president of research site development, Slope, discusses the competition pharma companies and trial sponsors face when trying to become a sponsor of choice and build trust with sites and patients.

Here in New Jersey, our home base, summer is officially upon us, and the Canadian wildfire smoke has just cleared from the air. I’m sure the bird watchers would attest to the eager chirping as both wildlife and humans greedily enjoy the beautiful weather. But even as the seasons change, so does the technology that drives innovation, as coverage in the July issue of Pharmaceutical Executive® attests.

There are clear pathways that biopharma companies can take to sustain growth and remain competitive.

This month, we deliver deep dives into the industry's commercial output and outlook and how drugmakers are faring in their public trust mandate—two areas where respective growth pursuits can often go hand-in-hand.

As conference season ramps up, it's a good time to reflect on the impact advances in pharma have on patients.

This year marks my first involvement in Pharmaceutical Executive’s Emerging Pharma Leaders (EPL) Awards, and what a ride it has been. We received so many wonderful nominations, and it’s always humbling to learn about some of the intricacies of the research that’s being done as well as the accomplishments of both current leaders and up-and-coming leaders.

The importance of not over-expanding during development, launch.

The rise of DOLs doesn’t mean pharma should upend KOL approach.

Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.

Agility and better decisions depend on managing risk and gaining insights from data by prioritizing patient and end-user needs. Companies of all sizes, including GSK, Boehringer-Ingelheim, Sanofi, AstraZeneca, and AbbVie, share best practices.